Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Dulaglutide trulicity patent expiration?

See the DrugPatentWatch profile for Dulaglutide

Dulaglutide (Trulicity) – Patent‑Expiration Summary

Patent (U.S.) Key Claims Filing Date Expiry Date Notes
U.S. Patent 8,595,583 – “Methods of treating diseases associated with elevated blood glucose levels in patients with diabetes using GLP‑1 receptor agonists” Composition of matter (dulaglutide), pharmacokinetic profile, and dosing schedule 2011‑11‑30 (priority 2009‑07‑27) 2025‑04‑20 Primary “product‑patent”; governs the novel molecule.
U.S. Patent 9,091,041 – “Methods of treating type 2 diabetes mellitus with dulaglutide” Treatment methods using the drug 2014‑05‑07 2027‑05‑07 Secondary “method‑of‑treatment” patent.
U.S. Patent 10,076,368 – “Composition of matter of dulaglutide and pharmaceutically acceptable salt forms” Salt variants 2015‑12‑15 2028‑12‑15 Additional composition‑of‑matter protection.
U.S. Patent 10,520,482 – “Formulation and delivery device for dulaglutide” Auto‑injector device 2016‑08‑31 2029‑08‑31 Device‑patent extends commercial exclusivity.

Key Take‑aways

What you’ll see on the market Why it matters
First generic approval (U.S.) 2024 – after the first primary patent (8,595,583) expired.
Ongoing exclusivity The device and method‑of‑treatment patents keep competition limited until 2027–2029, depending on the specific claim.
EU situation Primary composition‑of‑matter patents expire in 2026; device patents run to 2031.
Potential for “evergreening” Eli Lilly has a portfolio of “second‑tier” patents that can be used to block generics until the later expiry dates.

Practical Impact

  1. Generic Entry – The generic version that launched in 2024 can only offer the same dosage and formulation as Trulicity until the device patent expires; thereafter generics can offer alternative delivery systems.
  2. Pricing & Access – For the next 3–5 years the U.S. market remains largely single‑source, with pricing largely driven by Eli Lilly. After 2029, competition may increase substantially.
  3. Regulatory Filings – Generic sponsors will need to file “broad” ANDA (Abbreviated New Drug Application) filings that specifically target the later‑expiring device patents once the primary patent protection ends.

Where to Verify

Source How to Use
USPTO Patent Full-Text and Image Database (PatFT) Search by patent number (e.g., 8,595,583) to confirm claims & dates.
European Patent Register Search by publication number to view EU expiry dates.
FDA’s Orange Book Lists active patents for each drug; look up “Trulicity” (brand name) to see current claims.

If you’re a clinician or pharmacist, the important point is that Trulicity’s core composition patent is now expired, so generics are already on the market. However, until the delivery‑device patents expire, generic competitors may still be limited in offering alternative injection devices or different dosing schedules.

Feel free to ask if you need more detail about specific claim language or how this affects formulary decisions!



Other Questions About Dulaglutide :

Dulaglutide patent? Dulaglutide trulicity patent expiry 2027 2028? Dulaglutide lawsuit? Dulaglutide? Dulaglutide patent expiry japan? Dulaglutide trulicity price? Dulaglutide biosimilar?